Contact:
4008465777
-
About Us
News & Events
-
12-07
Tonghua Dongbao and Kexing Biopharm team up to fast-track product expansion abroad
On December 6, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) and Kexing Biopharm Co., Ltd. (“Kexing Biopharm”) signed the Exclusive License Agreement for Li...
-
11-15
Tonghua Dongbao receives the registration approval for premixed insulin aspart injections
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate from the National Medical Products Administrati...
-
10-31
Tonghua Dongbao: Q3 performance improves QoQ, with insulin analog sales doubling
Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as “Tonghua Dongbao” or the “Company”) released its quarterly report for Q3 2022 on October 30. According to t...
-
10-12
Tonghua Dongbao obtains the Pharmaceutical Product Registration Certificate for repaglinide tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate for repaglinide tablets issued by the National ...
-
09-21
Tonghua Dongbao: Clinical trial application for insulin degludec injection approved
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") received the notification of approval (No. 2022LP01532 and No. 2022LP01538) from the Center for Drug...
-
08-30
Tonghua Dongbao becomes the first Chinese manufacturer to have its clinical trial application for insulin degludec and liraglutide injection accepted
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") received the notification of acceptance from the Center for Drug Evaluation (CDE) of the National Me...